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Background
Headache is an extremely common neurological pro-
blem. Italy is the first European country for OTC con-
sumption with related problems of self-medication and
risk of medication overuse headache (MOH).
Aim
to monitor the consumption of symptomatic drugs for
headache and to prevent drugs abuse/dependence.
Materials and methods
274 patients using symptomatic drug for headache were
recruited in 32 pharmacies in the Pavia Health District.
A telephonic interview was carried out in 199 patients;
179 entered the study at baseline (T0) and 112 (22 M
and 90 F, mean age 45.0 ± 11.5 yrs.) were followed-up at
6 months (T6).
Results
patients with chronic migraine or MOH at T0 were 39
and 7 at T6. Days/month with headache at T6 vs T0
were 4.3 ± 0.6 vs 9.7 ± 0.8 (p < 0.0001). Attacks/month at
T6 vs T0 were slightly reduced (1.9 ± 0.2 vs 7.6 ± 0.8 p =
0.09). A significant decrease of the doses of analgesics
consumption/month was noted (T6 = 13.2 ± 1.2 vs T0 =
17.0 ± 2.2, p = 0.013). An increase in quality of life was
found on MIDAS scores at T6 vs T0 (13.4 ± 1.8 vs 23.7 ±
2.5; p = 0.00) and in the quality of treatment received
(HURT)(5.6 ± 0.4 vs 9.9 ± 0.5; p = 0.00).
Conclusions
Our results highlight that the change from self medica-
tion to medical care may reduce the numbers of
symptomatic treatment, the headache days/ month and
ameliorate the quality of life in patients with headache.
A longer follow-up (i.e. 12 month) may provide further
evidence on improvement of the clinical picture of
headache patients and prevention of MOH.
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